methoxsalen

Small moleculeapproved

Approved

Dec 3, 1954

Methoxsalen — also called xanthotoxin, marketed under the trade names Oxsoralen, Deltasoralen, Meladinine — is a drug used to treat psoriasis, eczema, vitiligo, and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, allegedly clearing up the disease. The dosage comes in 10 mg tablets, which are taken in the amount of 30 mg 75 minutes before a PUVA (psoralen + UVA) light treatment. Chemically, methoxsalen belongs to a class of organic natural molecules known as furanocoumarins. They consist of coumarin annulated with furan. It can also be injected and used topically. The exact mechanism of action of methoxsalen with the epidermal melanocytes and keratinocytes is not known. The best known biochemical reaction of methoxsalen is with DNA. Methoxsalen, upon photoactivation, conjugates and forms covalent bonds with DNA which leads to the formation of both monofunctional (addition to a single strand of DNA) and bifunctional adducts (crosslinking of psoralen to both strands of DNA) Reactions with proteins have also been described. Methoxsalen acts as a photosensitizer. Administration of the drug and subsequent exposure to UVA can lead to cell injury. Orally administered methoxsalen reaches the skin via the blood and UVA penetrates well into the skin. If sufficient cell injury occurs in the skin, an inflammatory reaction occurs. The most obvious manifestation of this reaction is delayed erythema, which may not begin for several hours and peaks at 48–72 hours. The inflammation is followed, over several days to weeks, by repair which is manifested by increased melanization of the epidermis and thickening of the stratum corneum. The mechanisms of therapy are not known. In the treatment of vitiligo, it has been suggested that melanocytes in the hair follicle are stimulated to move up the follicle and to repopulate the epidermis. In the treatment of psoriasis, the mechanism is most often assumed to be DNA photodamage and resulting decrease in cell proliferation but other vascular, leukocyte, or cell regulatory mechanisms may also be playing some role. Psoriasis is a hyperproliferative disorder and other agents known to be therapeutic for psoriasis are known to inhibit DNA synthesis. The most commonly reported side effect of methoxsalen alone is nausea, which occurs with approximately 10% of all patients. This effect may be minimized or avoided by instructing the patient to take methoxsalen with milk or food, or to divide the dose into two portions, taken approximately one-half hour apart. Other effects include nervousness, insomnia, and psychological depression. — NCATS

Clinical trial activity

27 trials · 35 clinical orgs · 9 marketing orgs

Phase 1
3
Phase 2
23
Phase 3
6
Phase 4
2

Earliest trial started Feb 1, 1996 (NCT00004359)

Timeline

1950s

  1. Dec 3, 1954

    Earliest FDA Approval

  2. Dec 3, 1954

    Bausch Health Companies — NDA Secondary Org

1980s

  1. Oct 30, 1986

    Dow Pharmaceutical Sciences — NDA Secondary Org

  2. Oct 30, 1986

    Bausch Health Companies — Marketing Organization

1990s

  1. Jan 1, 1996

    Earliest Phase 2 Sponsor(trial)

  2. Feb 25, 1999

    Mallinckrodt — NDA Secondary Org

  3. Feb 25, 1999

    International Minerals and Chemical Corporation — NDA Secondary Org

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jun 5, 2014

    Strides Pharma Science — Marketing Organization

  2. Jun 9, 2015

    Actavis — Marketing Organization

  3. Jun 9, 2015

    Allergan PLC (2015) — Marketing Organization

Indications

Mechanism of action

  • DNAINHIBITOR

    DNA inhibitor

Approval history

  • approvedPriority reviewDec 3, 1954

Chemistry & pharmacology

Loading structure…

SMILES

COC1=C2OC(=O)C=CC2=CC3=C1OC=C3
Mol. weight
216.1895 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4-methoxy-7h-furo(3,2-g)(1)benzopyran-7-one
  • 5-methoxy-6,7-furanocoumarin
  • 5 methoxypsoralen
  • 5 methoxypsoralen
  • 5-methoxypsoralen
  • 5-methoxypsoralen
  • 5-methoxypsoralen
  • 5-methoxypsoralen
  • 5-methoxypsoralen
  • 6-hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone
  • 6-hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone
  • 8-methoxy-2',3',6,7-furocoumarin
  • 8-methoxy-2',3',6,7-furocoumarin
  • 8-methoxy-4',5':6,7-furocoumarin
  • 8-methoxy-4',5':6,7-furocoumarin
  • 8-methoxy-[furano-3'.2':6.7-coumarin]
  • 8-methoxy-[furano-3'.2':6.7-coumarin]
  • 8-methoxyfuranocoumarin
  • 8-methoxyfuranocoumarin
  • 8-methoxypsoralen
  • 8-methoxypsoralen
  • 8-methoxypsoralen
  • 8-methoxypsoralen
  • 8-methoxypsoralen
  • 8-methoxypsoralene
  • 8-mop
  • 8-mop
  • 8-mop
  • 8-mop
  • 8-mop
  • 8-mop
  • 8-mop
  • 8-mp
  • 8-mp
  • 9-methoxy-7h-furo[3,2-g][1]benzopyran-7-one
  • 9-methoxy-7h-furo[3,2-g][1]benzopyran-7-one
  • ammoidin
  • ammoidin
  • bergaptan
  • bergapten
  • bergapten
  • bergapten
  • bergapten
  • bergapten
  • bergapten
  • bergapten
  • bergaptene
  • cis,trans-xanthoxin
  • deltapsoralen
  • deltasoralen
  • deltasoralen
  • heraclin
  • meladinin
  • meladinine
  • meladinine
  • meladinine
  • meladinine
  • meladoxen
  • meloxine
  • meloxine
  • meloxine
  • methosaxalen
  • methoxalen
  • methoxalen
  • methoxsalen
  • methoxsalen
  • methoxsalen
  • methoxsalen
  • methoxsalen
  • methoxsalen
  • methoxsalen
  • methoxsalen
  • methoxsalen
  • methoxsalene
  • méthoxsalène
  • méthoxsalène
  • methoxypsoralen
  • methoxypsoralen
  • o-methylxanthotoxol
  • o-methylxanthotoxol
  • oxsoralen
  • oxsoralen
  • oxsoralen
  • oxsoralen
  • oxsoralen-ultra
  • oxsoralen-ultra
  • puvasoralen-8
  • trans,trans-5-(1',2'-epoxy-4'-hydroxy-2',6',6'- trimethyl-1'-cyclohexyl)-3-methylpentadienal
  • trans,trans-xanthoxin
  • ultra mop
  • ultra mop
  • uvadex
  • uvadex
  • xanthotoxin
  • xanthotoxin
  • xanthotoxin
  • xanthotoxin
  • xanthotoxine
  • xanthotoxine
  • xanthotoxine
  • xanthoxin
  • xanthoxin
  • xanthoxin
  • xanthoxin, (1r-(1alpha(2e,4e),4beta,6alpha))-isomer
  • xanthoxin, (1s-(1alpha(2e,4e),4alpha,6alpha))-isomer
  • xanthoxin, (1s-(1alpha(2z,4e),4alpha,6alpha))-isomer
  • zanthotoxin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06646016Phase 2Jan 31, 2025Mallinckrodt
NCT04986605Phase 2Mar 31, 2022Mallinckrodt, University of Western Ontario
NCT05680558Phase 2May 8, 2021Columbia University, Mallinckrodt
NCT03778996Phase 2May 31, 2019Joseph Ahmed Foundation (JAF), Sarcoma Oncology Research Center, LLC, Tyme, Inc
NCT03563040Phase 2Dec 1, 2018European Organisation for Research and Treatment of Cancer, Karl Landsteiner Private University of Health Sciences, Mallinckrodt, Medical University of Vienna
NCT03605940Phase 2Oct 1, 2018University of Lorraine
NCT03512756Phase 2Mar 27, 2018Tyme, Inc
NCT02562612Phase 1/Phase 2 (Phase 2)Oct 1, 2016Tyme, Inc
NCT02524847Phase 3Sep 1, 2015Mallinckrodt, Vanderbilt University
NCT02322190Phase 2Dec 4, 2014National Cancer Institute (NCI)
NCT01686594Phase 3Feb 1, 2013Medical University of Graz
NCT01380535Phase 1Nov 1, 2011Mallinckrodt, Parexel
NCT00930566Phase 1/Phase 2 (Phase 2)Apr 1, 2009Etablissement Français du Sang, University of Lyon
NCT00639717Phase 2Mar 1, 2009Amgen, Mallinckrodt, University of Michigan
NCT00811005Phase 3Oct 1, 2008University of Vienna
NCT00533195Phase 3Oct 1, 2007University of Vienna
NCT00282503Phase 3Jan 1, 2006Mallinckrodt, Pharmaceutical Research Associates, Inc. (PRA)
NCT00221026Phase 2Dec 1, 2004ICON, Mallinckrodt
NCT00221039Phase 4Sep 1, 2004Boston University, Case Western Reserve University, Mallinckrodt, Rush University, University of Minnesota, University of Pittsburgh, University of Texas at Houston, Vanderbilt University
NCT00221000Phase 2Aug 1, 2003Mallinckrodt, Rebecca MacDonald Centre for Arthritis
Showing 20 of 27 trials
Page 1 / 2

Organizations

Research & Development (35)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MallinckrodtFor profit141051999
Tyme, IncFor profit3212016
European Organisation for Research and Treatment of CancerAcademic/Hospital2222003
Northwestern UniversityAcademic/Hospital2011996
University of ViennaAcademic/Hospital2212007
Vanderbilt UniversityAcademic/Hospital2022004
AmgenFor profit1012009
Boston UniversityAcademic/Hospital1012004
Case Western Reserve UniversityAcademic/Hospital1012004
Columbia UniversityAcademic/Hospital1112021
Etablissement Français du SangAcademic/Hospital1012009
ICONFor profit1012004
Joseph Ahmed Foundation (JAF)Academic/Hospital1012019
Karl Landsteiner Private University of Health SciencesAcademic/Hospital1012018
Madrilenian Group of Cutaneous LymphomasAcademic/Hospital1112000
Medical University of GrazAcademic/Hospital1112013
Medical University of ViennaAcademic/Hospital1012018
MillennixFor profit1112001
National Cancer Institute (NCI)Government1112014
National Center for Research Resources (NCRR)Government1111996
35 organizations
Page 1 / 2

Marketing (10)

OrganizationOrg typeRelationshipDate
ActavisFor profitMKTGJun 9, 2015
Allergan PLC (2015)For profitMKTGJun 9, 2015
Ani PharmaceuticalsFor profitMKTG
Bausch Health CompaniesFor profitNDA2Dec 3, 1954
Bausch Health CompaniesFor profitMKTGOct 30, 1986
Dow Pharmaceutical SciencesFor profitNDA2Oct 30, 1986
International Minerals and Chemical CorporationFor profitNDA2Feb 25, 1999
MallinckrodtFor profitNDA2Feb 25, 1999
Paul B Elder CompanyFor profitNDA
Strides Pharma ScienceFor profitMKTGJun 5, 2014